BillionToOne
BillionToOne is a cutting-edge molecular diagnostics company dedicated to transforming healthcare with innovative and accessible diagnostic tests. They foster a culture of transparency, collaboration, and purpose-driven work, aiming to build products that significantly improve patient outcomes in prenatal and cancer diagnostics.
Headquarters
Menlo Park, California, United States
Company Size
201-500 employees
Founded
2016
BillionToOne is a molecular diagnostics company that develops blood-based tests for prenatal screening and oncology, with a focus on detecting rare genetic variants in cell-free DNA. Its proprietary Quantitative Counting Template technology powers noninvasive prenatal screening and liquid biopsy assays used by healthcare providers and clinical laboratories. The company operates in the genomics and precision diagnostics industry.
BillionToOne Market Share Gains Raise Questions On Undervalued BLLN Stock
4 days ago
BillionToOne valued at $4.4 billion as shares surge in blockbuster Nasdaq debut
Nov 6, 2025
BillionToOne’s Single-Molecule Next-Generation Sequencing Platform Redefines Molecular Diagnostics for Prenatal and Oncology Care 404148
9 hours ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for BillionToOne.
BillionToOne Shares Surge Following Firm's $273M IPO
Nov 6, 2025
Senior Staff Scientist, IVD Assay Verification and Validation (Contract)
DELFI Diagnostics, Inc.
Translational Scientist - Hybrid
Caris Life Sciences
Lead Genetic Counselor
Columbia University
Regional Oncology Account Executive, MRD- Southwest (U.S. Field Based)
SAGA Diagnostics
Director - BioPartnering Solutions
Caris Life Sciences
Translational Scientist - LDT (Hybrid)
Caris Life Sciences